Literature DB >> 20658525

MiR-125b targets BCL3 and suppresses ovarian cancer proliferation.

Yi Guan1, Hailan Yao, Zhihong Zheng, Guangrong Qiu, Kailai Sun.   

Abstract

Micro-RNAs (miRNAs) important for post-transcriptional gene expression as negative regulators are endogenous 21- to 23-nucleotide noncoding RNAs. Many miRNAs are expressed in ovarian cancer (OC). In this study, we reported that miR-125b was underexpressed in human OC specimens. Ectopic expression of miR-125b in OC cells induced cell cycle arrest and led to reduction in proliferation and clonal formation. This inhibitory effect on OC cell growth was mediated by miR-125b inhibition of the translation of an mRNA encoding a proto-oncogene, BCL3. Furthermore, expression of miR-125b suppressed the tumor formation generated by injecting OC cells in nude mice. Our results suggest that aberrantly expressed miR-125b may contribute to OC development.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20658525     DOI: 10.1002/ijc.25575

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  72 in total

1.  CFTR mediates bicarbonate-dependent activation of miR-125b in preimplantation embryo development.

Authors:  Yong Chao Lu; Hui Chen; Kin Lam Fok; Lai Ling Tsang; Mei Kuen Yu; Xiao Hu Zhang; Jing Chen; Xiaohua Jiang; Yiu Wa Chung; Alvin Chun Hang Ma; Anskar Yu Hung Leung; He Feng Huang; Hsiao Chang Chan
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

2.  Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action.

Authors:  Seyed H Ghaffari; Davood Bashash; Majid Zaki Dizaji; Ardeshir Ghavamzadeh; Kamran Alimoghaddam
Journal:  Tumour Biol       Date:  2011-11-10

3.  MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets.

Authors:  A G Lisa Ooi; Debashis Sahoo; Maddalena Adorno; Yulei Wang; Irving L Weissman; Christopher Y Park
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-30       Impact factor: 11.205

4.  MicroRNA-125b potentiates macrophage activation.

Authors:  Aadel A Chaudhuri; Alex Yick-Lun So; Nikita Sinha; William S J Gibson; Konstantin D Taganov; Ryan M O'Connell; David Baltimore
Journal:  J Immunol       Date:  2011-10-14       Impact factor: 5.422

Review 5.  Pivotal MicroRNAs in Melanoma: A Mini-Review.

Authors:  Zhenjun Deng; Jingang Hao; Dongyun Lei; Yongjing He; Lechun Lu; Li He
Journal:  Mol Diagn Ther       Date:  2016-10       Impact factor: 4.074

Review 6.  Aberrantly expressed microRNAs in bladder cancer and renal cell carcinoma.

Authors:  Akira Kurozumi; Yusuke Goto; Atsushi Okato; Tomohiko Ichikawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2016-06-30       Impact factor: 3.172

7.  miR-133a suppresses ovarian cancer cell proliferation by directly targeting insulin-like growth factor 1 receptor.

Authors:  Jinling Guo; Bairong Xia; Fanling Meng; Ge Lou
Journal:  Tumour Biol       Date:  2013-10-15

8.  The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.

Authors:  Yue Zou; Mohammad M Uddin; Sveta Padmanabhan; Yan Zhu; Pengli Bu; Ales Vancura; Ivana Vancurova
Journal:  J Biol Chem       Date:  2018-08-22       Impact factor: 5.157

9.  Prognostic marker microRNA-125b inhibits tumorigenic properties of hepatocellular carcinoma cells via suppressing tumorigenic molecule eIF5A2.

Authors:  Felice H Tsang; Victor Au; Wen-Jing Lu; Felix H Shek; Angela M Liu; John M Luk; Sheung-Tat Fan; Ronnie T P Poon; Nikki P Lee
Journal:  Dig Dis Sci       Date:  2014-05-09       Impact factor: 3.199

10.  MicroRNA-125b inhibits the proliferation of vascular smooth muscle cells induced by platelet-derived growth factor BB.

Authors:  Xiaogao Wang; Shiyuan Chen; Yong Gao; Chaowen Yu; Zhonglin Nie; Ran Lu; Yong Sun; Zeyu Guan
Journal:  Exp Ther Med       Date:  2021-05-24       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.